Favorable effects of ezetimibe alone or in association with simvastatin on the removal from plasma of chylomicrons in coronary heart disease subjects

Atherosclerosis

Volumn 233, Issue 1, 2014, Pages 319-325

  Mangili, Otavio Celeste ^a   Moron Gagliardi, Ana C ^a   Mangili, Leonardo Celeste ^a   Mesquita, Carlos H ^b   Machado Cesar, Luiz A ^a   Tanaka, Akira ^c   Schaefer, Ernst J ^d   Maranhão, Raul C ^a   Santos, Raul D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^c KAGAWA NUTRITION UNIVERSITY   (Japan)

^d TUFTS UNIVERSITY   (United States)

Author keywords

ApoB 48; Chylomicrons; Emulsions; Ezetimibe; Simvastatin; Triglyceride rich lipoproteins

Indexed keywords

APOB-48; CHYLOMICRONS; EMULSIONS; EZETIMIBE; SIMVASTATIN; TRIGLYCERIDE-RICH LIPOPROTEINS;

AGED; AZETIDINES; CHOLESTEROL ESTERS; CHYLOMICRON REMNANTS; CHYLOMICRONS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KINETICS; MALE; MIDDLE AGED; SIMVASTATIN; TRIGLYCERIDES; TRIOLEIN;

EID: 84893876799     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.12.008     Document Type: Article

References (40)

1. Groot P.H., van Stiphout W.A., Krauss X.H., et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 1991, 11:653-662.
2. Gouni-Berthold I., Berthold H.K., Gylling H., et al. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis 2008, 198:198-207.
3. Patsch J.R., Miesenbock G., Hopferwieser T., et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992, 12:1336-1345.
4. Weintraub M.S., Grosskopf I., Rassin T., et al. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. BMJ 1996, 312(7036):935-939.
5. Maranhao R.C., Feres M.C., Martins M.T., et al. Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease. Atherosclerosis 1996, 126:15-25.
6. Van Lenten B.J., Fogelman A.M., Jackson R.L., et al. Receptor-mediated uptake of remnant lipoproteins by cholesterol-loaded human monocyte-macrophages. JBiol Chem 1985, 260:8783-8788.
7. Dallinga-Thie G.M., Franssen R., Mooij H.L., et al. The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight. Atherosclerosis 2010, 211:1-8.
8. Bishop J.R., Stanford K.I., Esko J.D. Heparan sulfate proteoglycans and triglyceride-rich lipoprotein metabolism. Curr Opin Lipidol 2008, 19:307-313.
9. Niemeier A., Gafvels M., Heeren J., Meyer N., Angelin B., Beiseigel U. VLDL receptor mediates the uptake of human chylomicron remnants invitro. JLipid Res 1996, 37:1733-1742.
10. Cianflone K., Bilodeau M., Davignon J., et al. Modulation of chylomicron remnant metabolism by an hepatic hydroxymethylglutaryl coenzyme A reductase inhibitor. Metabolism 1990, 39:274-280.
11. Santos R.D., Sposito A.C., Ventura L.I., et al. Effect of pravastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease. Am J Cardiol 2000, 85:1163-1166.
12. Sposito A.C., Santos R.D., Amancio R.F., et al. Atorvastatin enhances the plasma clearance of chylomicron-like emulsions in subjects with atherogenic dyslipidemia: relevance to the invivo metabolism of triglyceride-rich lipoproteins. Atherosclerosis 2003, 166:311-321.
13. Knopp R.H., Dujovne C.A., Le Beaut A., et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003, 57:363-368.
14. Goldberg R.B., Guyton J.R., Mazzone T., et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 2006, 81:1579-1588.
15. Catapano A.L., Davidson M.H., Ballantyne C.M., et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006, 22:2041-2053.
16. van Heek M., Farley C., Compton D.S., et al. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001, 134:409-417.
17. Santos R.D., Ventura L.I., Sposito A.C., et al. The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia. Cardiovasc Res 2001, 49:456-465.
18. Carneiro M.M., Miname M.H., Gagliardi A.C., et al. The removal from plasma of chylomicrons and remnants is reduced in heterozygous familial hypercholesterolemia subjects with identified LDL receptor mutations: study with artificial emulsions. Atherosclerosis 2012, 221:268-274.
19. Sposito A.C., Santos R.D., Hueb W., et al. LDL concentration is correlated with the removal from the plasma of a chylomicron-like emulsion in subjects with coronary artery disease. Atherosclerosis 2002, 161:447-453.
20. Sposito A.C., Ventura L.I., Vinagre C.G., et al. Delayed intravascular catabolism of chylomicron-like emulsions is an independent predictor of coronary artery disease. Atherosclerosis 2004, 176:397-403.
21. Sposito A.C., Lemos P.A., Santos R.D., et al. Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment: a long-term follow-up study. JAm Coll Cardiol 2004, 43:2225-2232.
22. Cesar T.B., Oliveira M.R., Mesquita C.H., et al. High cholesterol intake modifies chylomicron metabolism in normolipidemic young men. JNutr 2006, 136:971-976.
23. Yunoki K., Nakamura K., Miyoshi T., et al. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis 2011, 217:486-489.
24. Tremblay A.J., Lamarche B., Hogue J.C., et al. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. JLipid Res 2009, 50:1463-1471.
25. McGowan M.P. There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation 2004, 110:2333-2335.
26. ICRP Publication 113 Education and training in radiological protection for diagnostic and interventional procedures. Ann ICRP 2009, 39:7-68.
27. Redgrave T.G., Maranhao R.C. Metabolism of protein-free lipid emulsion models of chylomicrons in rats. Biochim Biophys Acta 1985, 835:104-112.
28. Redgrave T.G., Zech L.A. Akinetic model of chylomicron core lipid metabolism in rats: the effect of a single meal. JLipid Res 1987, 28:473-482.
29. Schwartz C.C., VandenBroek J.M., Cooper P.S. Lipoprotein cholesteryl ester production, transfer, and output invivo in humans. JLipid Res 2004, 45:1594-1607.
30. 137C transfer rates in marine organisms and dose in man. JRadioanal Nucl Chem 1998, 232:233-236.
31. 14C] cholesterol in humans. Nukleonika 2012, 57:607-613.
32. Chan D.C., Watts G.F., Barrett P.H., et al. Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. JLipid Res 2002, 43:706-712.
33. Altmann S.W., Davis H.R., Zhu L.J., et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-1204.
34. Telford D.E., Sutherland B.G., Edwards J.Y., et al. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. JLipid Res 2007, 48:699-708.
35. Tremblay A.J., Lamarche B., Cohn J.S., et al. Effect of ezetimibe on the invivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006, 26:1101-1106.
36. Le N.A., Innis-Whitehouse W., Li X., Bakker-Arkema R., Black D., Brown W.V. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism 2000, 49:167-177.
37. Nakou E.S., Filippatos T.D., Agouridis A.P., Kostara C., Bairaktari E.T., Elisaf M.S. The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids 2010, 45:445-450.
38. Imagawa M., Takahashi S., Zenimaru Y., et al. Comparative reactivity of remnant-like lipoprotein particles (RLP) and low-density lipoprotein (LDL) to LDL receptor and VLDL receptor: effect of a high-dose statin on VLDL receptor expression. Clin Chim Acta 2012, 413:441-447.
39. Otokozawa S., Ai M., Van Himbergen T., et al. Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels. Atherosclerosis 2009, 205:197-201.
40. Graham D.J., Staffa J.A., Shatin D., et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAm Med Assoc 2004, 292:2585-2590.